FCGR2C: A Potential Drug Target for Cancer and Other Diseases

Target Name: FCGR2C

NCBI ID: G9103

FCGR2C

FCGR2C: A Potential Drug Target for Cancer and Other Diseases

FCGR2C, also known as FCGR2C variant 1, is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer. The FCGR2C gene is located on chromosome 6 and encodes for a protein known as furin, which is a transmembrane protein that is involved in various cellular processes, including cell signaling, angiogenesis, and inflammation.

The FCGR2C gene was first identified in 2015 as a potential gene that could serve as a drug target or biomarker for various diseases, including cancer. Researchers found that the gene was expressed in a variety of tissues and cells, including brain, heart, liver, and cancer cells. Additionally, the gene was shown to be involved in the development and progression of various diseases, including cancer.

One of the key reasons why FCGR2C has potential as a drug target is its involvement in cell signaling. The furin protein is known to play a role in cell signaling, particularly in the regulation of angiogenesis, which is the process by which new blood vessels are formed. This is important because angiogenesis is often associated with the development and progression of diseases, including cancer.

Another potential mechanism by which FCGR2C could be used as a drug target is its role in inflammation. The furin protein has been shown to be involved in the regulation of inflammation and inflammation-related signaling pathways. This is important because inflammation is often associated with the development and progression of diseases, including cancer.

In addition to its potential role in cell signaling and inflammation, FCGR2C has also been shown to be involved in the regulation of cell adhesion. The furin protein is known to play a role in the regulation of cell adhesion, which is the process by which cells stick together and form tissues. This is important because cell adhesion is often associated with the development and progression of diseases, including cancer.

Overall, FCGR2C is a gene that has a potential role as a drug target or biomarker for various diseases, including cancer. Its involvement in cell signaling, angiogenesis, inflammation, and cell adhesion make it an attractive target for researchers to investigate further. As further research is conducted, it is likely that the potential benefits of FCGR2C as a drug or biomarker will be realized.

Protein Name: Fc Gamma Receptor IIc (gene/pseudogene)

Functions: Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells

The "FCGR2C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FCGR2C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets